European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly lower Wednesday morning, declining 0.36% to 1,359.56 on the S&P Europe Select ADR Index. From continental Euro
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
WHO Picks JN.1 Variant for Next Set of COVID Vaccines
Pfizer and BioNTech Shares Are Trading Lower Amid Reports GSK Is Suing the Companies Alleging Patent Infringement Concerning MRNA Technology Used in Their COVID-19 Vaccines.
Pfizer and BioNTech Shares Are Trading Lower Amid Reports GSK Is Suing the Companies Alleging Patent Infringement Concerning MRNA Technology Used in Their COVID-19 Vaccines.
Update: GSK Sues Pfizer, BioNTech Over MRNA Patents in Covid-19 Vaccines
GlaxoSmithKline sues Pfizer and BioNTech over mRNA vaccine technology
GLONGHUI, April 25 | GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing on the company's patents relating to RNA (mRNA) technology. GlaxoSmithKline claims Pfizer's and BioNTech's ComirNaty vaccine infringes on the company's patent for an mRNA vaccine innovation developed “more than a decade before the COVID-19 pandemic broke out.” A Pfizer spokesperson said in a statement that they are confident of our intellectual property position in Comirnaty and intend to make a “strong defense” against GlaxoSmithKline's claim.
Scholz Promises Support for Pharma Sector in Germany as Merck Invests
BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.'
Pfizer Vs Moderna Battle Over COVID Vaccine Patents Begins in UK
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company
Assessing BioNTech: Insights From 11 Financial Analysts
Ratings for BioNTech (NASDAQ:BNTX) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
HC Wainwright & Co. : The BioNTech (BNTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $107.00.
HC Wainwright & Co. : The BioNTech (BNTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $107.00.
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $107 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $107 price target.
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB) and Clene (CLNN) with bullish sentiments.
TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio,
BioNTech SE Virtual AGM Scheduled for May 2024
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer
BioNTech (BNTX) said Sunday that three-year follow-up data from a phase 1 trial on its immunotherapy candidate cevumeran in patients with resected pancreatic ductal adenocarcinoma, or PDAC, showed tha
Express News | BioNTech says data from the cancer vaccine candidate BNT122 showed positive results.
Three-year Phase 1 Follow-Up Data for MRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients With Resected Pancreatic Cancer
BioNTech SE (Nasdaq: BNTX) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy ("iNeST") candidate autogene cevumeran (also known as BNT122, RO7198457) in patients with resected pancreatic ductal adenocarcinoma ("PDAC").
No Data